Related Experiment Video
Updated: Sep 21, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma
Ken Ito1,2, Hirotaka Ishida1,2, Fumiyoshi Fujishima2
1Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Background/Aim:
Murine double minute 2 (MDM2) is well known to inhibit p53 function and its over-expression is associated with poor prognosis in several human malignancies. Nutlin-3, a small-molecule inhibitor of MDM2, exerts antitumor effects on various solid tumors harboring wild-type p53. We aimed to clarify its effects on esophageal cancer.
Materials And Methods:
We first examined the potential antitumor effects of nutlin-3 according to MDM2 status using esophageal carcinoma cell lines (KYSE 170/180). We then immunolocalized MDM2 immunoreactivity in 62 surgical cases of esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy and correlated the findings with clinicopathological variables.
Results:
MDM2 mRNA expression in KYSE 170 was significantly higher than that in KYSE 180 cells. No significant changes were detected in both cell lines when nutlin-3 was added. However, cell proliferation was significantly decreased in KYSE 170 cells treated with nutlin-3 and cisplatin compared to cisplatin alone but not in KYSE 180. MDM2 immunoreactivity was also significantly associated with poor sensitivity to neoadjuvant chemotherapy in the cases examined.
Conclusion:
The combination of nutlin-3 with chemotherapeutic agents may become a novel therapeutic strategy in esophageal cancer over-expressing MDM2.
Insights
Nutlin-3 combined with chemotherapy shows promise for esophageal cancer overexpressing Murine double minute 2 (MDM2). This combination reduced cell proliferation in MDM2-high cells, suggesting a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Murine double minute 2 (MDM2) inhibits p53, and its overexpression correlates with poor prognosis in malignancies.
- Nutlin-3, an MDM2 inhibitor, has shown antitumor effects in solid tumors with wild-type p53.
- Esophageal cancer's response to MDM2 inhibition requires further investigation.
Purpose of the Study:
- To evaluate the antitumor effects of Nutlin-3 in esophageal cancer.
- To assess the role of MDM2 expression in treatment response.
- To explore combination therapy with Nutlin-3 and cisplatin.
Main Methods:
- Assessed Nutlin-3 effects on esophageal carcinoma cell lines (KYSE 170/180) based on MDM2 status.
- Immunolocalized MDM2 in 62 esophageal squamous cell carcinoma cases.
- Correlated MDM2 expression with neoadjuvant chemotherapy response.
Main Results:
- MDM2 mRNA was higher in KYSE 170 cells; Nutlin-3 alone showed no significant effect.
- Nutlin-3 plus cisplatin decreased proliferation in KYSE 170 cells but not KYSE 180.
- MDM2 immunoreactivity correlated with poor sensitivity to neoadjuvant chemotherapy.
Conclusions:
- Combination therapy with Nutlin-3 and chemotherapy may be a novel strategy for MDM2-overexpressing esophageal cancer.
- MDM2 status is a potential predictive biomarker for treatment response.
